[Efficacy of beta-blockers in infantile capillary haemangiomas: the physiopathological significance and therapeutic consequences].
Léauté-Labrèze
C
C
Unité de dermatologie pédiatrique, groupe hospitalier Pellegrin-Enfants, place Amélie-Raba-Léon, 33076 Bordeaux, France. christine.labreze@chu-bordeaux.fr
Taïeb
A
A
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000367:Age Factors; D017209:Apoptosis; D002648:Child; D002675:Child, Preschool; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol